Sinovac Biotech Ltd (SVA) stock

SVANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 5, 2026Score 6/30

$6.47+0.00 (0.00%)

Close on Nov 13, 2026Market cap $464.94MP/E –Yield 850.08%

Sinovac Biotech ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2012 it was -$16.66M, down 303.2% from the year before.

Period	Period end	Value	Change
FY2012	Dec 31, 2012	-$16.66M	-303.2%
FY2011	Dec 31, 2011	$8.20M	–
FY2010	Dec 31, 2010	-$9.12M	-120.6%
FY2009	Dec 31, 2009	$44.39M	–

Parsed from the XBRL in Sinovac Biotech's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SVA.

Revenue growth6.8% · median -2.1%

Gross margin67.9% · median 54.7%

Operating margin-127.0% · median -42.1%

Advertisement
300 × 250

See a number that looks wrong?